RadNet, Inc. Third Quarter 2026 Financial Results Conference Call - RADNET INC

Explicit Guidance:

• Imaging Center Segment (FY2026): Increased revenue guidance to $2.385B–$2.435B (up $15M low/high); adjusted EBITDA to $350M–$363M (up $5M low/high); CapEx to $170M–$180M (up $5M low/high); free cash flow to $120M–$130M (up $10M low/high).
• Digital Health Segment (FY2026): Reaffirmed revenue guidance of $135M–$145M; raised adjusted EBITDA (excl. capitalized R&D) to $11M–$13M (up from prior); increased CapEx guidance by $1M.
• Digital Health Segment (FY2027 Implication): Q4 ARR expected to reach >$140M (87% growth YoY); full-year 2026 revenue guidance implies a Q4 ramp.

Business-Segment Outlook:

• Imaging Centers: Expect continued growth in advanced imaging volumes (MRI, CT, PET-CT) in 2027 at current rates, driven by aging demographics and AI-enabled scanner speed (e.g., PET-CT scan times reduced to <15 mins). Capacity expansion via extended hours, new de novo centers (target increased from 7 to 10 in 2026), and tuck-in acquisitions.
• Digital Health: Revenue and EBITDA expected to ramp in Q4 2026 and into 2027 as Q3 ARR of $112.6M converts to GAAP revenue. Q4 2026 revenue expected to grow ~20% sequentially. Full-year 2026 revenue projected to be $135M–$145M.
• Radiology Professional Services (OnRad): Upon closing, OnRad expected to contribute $190M–$200M in revenue and $60M–$65M in adjusted EBITDA in the first year of operation. EBITDA target for 2027 earn-out is $56M; upside pays 15x the excess EBITDA.
• Product Pipeline: FDA clearances for breast arterial calcification (June), breast ultrasound (July), and next-gen chest X-ray (September). 28 FDA clearances and 26 CE marks currently held. Pending submissions in mammography, lung, neural, and prostate.

Market and Competitive Outlook:

• Advanced Imaging Demand: Disproportionately higher growth in MR, CT, and PET-CT relative to routine imaging; advanced imaging mix shifted from 28.2% to 30.6% of total procedural volume in Q3 2026.
• AI Integration: Goal to process >75% of RadNet studies via clinical AI by Q3 2027; aim for >50% imaging volume report automation by Q3 2027. Current coverage: >50% studies processed by AI; 30% exams covered by "Reporting Pro" (targeting full deployment by Q1 2027).
• Competitive Advantage: Leveraging tech shortage to offer end-to-end solutions combining imaging centers, professional services, and AI to health systems, addressing the lack of internal expertise among partners.

Macro / Industry Outlook:

• Medicare Rates (2027): Final rule released Nov 4, 2027, resulting in ~2.3% reduction in conversion factor ($33.40 to $32.63). Estimated negative revenue impact for RadNet is ~$5M. Management notes Congress may reverse this reduction in Dec legislative package; 2027 budget reflects final rule.
• Hospital Outpatient Prospective Payment System (HOPPS): Finalized site neutrality provision (reimbursing hospitals at lower physician fee schedule rates for non-contrast imaging) expected to drive more health system partnership discussions due to economic pressure on radiology departments.
• Labor Market: Persistent shortages of technologists and radiologists continue to pressure salaries and capacity, driving demand for AI, TechLive (remote technologists), and automation.

Strategic Initiatives:

• OnRad Acquisition: Pending acquisition of OnRad (tele-radiology, staffing, teleradiology final reads) expected to form third operating segment "Radiology Professional Services." Closing expected to provide immediate revenue/EBITDA accretion ($190M–$200M rev, $60M–$65M EBITDA Year 1).
• AI Deployment: Accelerated deployment of "Reporting Pro" to replace conventional reporting; rollout of breast ultrasound AI, thyroid ultrasound AI, and automated draft reporting. Goal to reduce reporting time by up to 30%.
• Operational Efficiency: Digital patient registration tool scaling to ~30 centers (pilot complete); target full RadNet rollout by end of Q1 2027. Digital scheduling to reduce contact center reliance.
• M&A Pipeline: Continued pursuit of tuck-in acquisitions and expansion of health system joint ventures; new JV pipeline includes existing partners and new customers attracted by OnRad announcement.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Potential lack of Congressional action to reverse Medicare reimbursement rate reductions could impact 2027 revenue beyond the estimated $5M.
• Acquisition Integration: Risks associated with integrating OnRad operations and realizing projected synergies (revenue/EBITDA).
• Operational Constraints: Past capacity constraints in implementation/service organizations (resolved in Q3) and potential future delays in technology rollout.
• Reimbursement Mix: Continued pressure on commercial payer reimbursements and site neutrality rules affecting health system economics.

Management Tone on the Future:

• Confidence: "Very confident" in delivering a record Q4 2026 revenue quarter (>40M implied); confident in 2027 growth trajectory driven by advanced imaging and AI.
• Strategic Conviction: Strong emphasis on AI as a fundamental solution to healthcare delivery; views the integration of clinical AI, agentic AI, and professional services as a "land and shift" strategy for hospital systems.
• Guidance Philosophy: Management reiterated that updated guidance adds Q3 beats to previous full-year ranges rather than re-forecasting remaining quarters; caution against implying margins for the rest of the year.

Miscellaneous:

• OnRad Valuation Terms: Purchase price is $350M cash + 5M shares; 2027 EBITDA earn-out of $56M target with 15x payout for excess.
• Gleamer Integration: 63 new customers added in Q3, nearly all net new (external); 30% of RadNet exams covered by Reporting Pro; goal to reach 30% automation on breast ultrasound and X-ray soon.
• Liquidity: $750.6M cash balance, $282M revolving credit facility availability; net debt/adjusted EBITDA leverage at 1.66x.